20

Jul2022

PDCI Launches Sharing Page for PMPRB Consultation Submissions

On June 30, 2022, PMPRB issued a Notice and Comment which published its Proposed Interim Guidance and invited stakeholder comments until July 18, 2022. This Interim Guidance outlines PMPRB’s intentions for regulating the prices of patented medicines in the “interim period” between the coming-into-force date ... Read More

28

Jun2022

PDCI welcomes François-Xavier Houde to the Team
 

François-Xavier has joined PDCI Market Access as a Senior Health Economist. He is responsible for leading the conception and development of strategic, evidence-based economic components for submission to Canadian Health Technology Assessment (HTA) bodies and public/private payers. Among other roles, he ensures that PDCI is ... Read More

20

Jun2022

PRESS RELEASE: PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch

Ottawa, June 20, 2022: PDCI study finds Canada Ranks 10th on its Attractiveness for New Medicine Launch Launched today by PDCI Market Access, a new study finds Canada ranks 10th out of 14 countries ... Read More

20

May2022

PDCI’s Biopharmaceutical Ecosystem Index
Part of a Lunch Time Educational Series
 

PDCI is excited to announce the launch of its new Webinar Series, kicking-off next month with the release of PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch?During this calendar year, PDCI will host quarterly, lunchtime educational webinars, covering issues of interest to ... Read More

05

May2022

CADTH Update: Advice on Real-World Evidence (RWE) by Scientific Advice Program

On May 3, 2022, CADTH announced the mandate expansion of the Scientific Advice Program to include advice on RWE generation plans after protocols for pivotal trials are finalized. What to know: The expanded program will run for a 1-year learning ... Read More

25

Apr2022

The PMPRB to consult on a different set of guidelines

On April 14, 2022, Health Canada announced that the government will:  Proceed only with the proposed amendments to the Regulations pertaining to schedule of reference countries (the PMPRB11 replacing the PMPRB7).   Not proceed with new excessive price factors (cost effectiveness, market size, GDP) nor the reporting of third-party ... Read More

04

Apr2022

PMPRB 2020 Annual Report Shows Almost 30% Decrease in New Patented Medicines Reported Since 2018

On March 31, 2022, PMPRB published its 2020 Annual Report on its website. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine investment and launch since drug pricing reform began in 2017. Statistical Highlights201820192020Total # of Patented Medicines for Human Use Reported ... Read More

25

Mar2022

Supreme Court Dismisses Attorney General’s Application for Leave to Appeal FCA decision in PMPRB Alexion Soliris Matter

On September 29, 2021, the Attorney General of Canada applied for leave to appeal to the Supreme Court of Canada concerning the Federal Court of Appeal’s (FCA) July 2021 decision in Alexion Pharmaceuticals Inc v Canada (Attorney General). On March 24, 2022, the Supreme Court of Canada ... Read More

23

Feb2022

New PDCI Market Access INSIGHTS (Volume 2, Issue 2)

PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. Volume 2, Issue 2 AnalyticsOur analytics article features ... Read More

22

Feb2022

Quebec Court Strikes 2 of 3 PMPRB Changes

On February 18, 2022, the Quebec Court of Appeal ruled that two of the three major proposed changes to the PMPRB price regulations are unconstitutional: As more information becomes available, PDCI will share further insights and implications for ... Read More